No writing assistance was utilized in the production of this manuscript. The blood–brain barrier (BBB) is a significant obstacle to therapeutic delivery for CNS disorders. Among various ...

This Hanson Wade event is aimed at experts looking to deliver CNS drug candidates safely and successfully across the blood-brain barrier (BBB). It will enable them understand the biology of the ...

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system.

The 3 rd Annual Blood-Brain Barrier Summit is dedicated to helping drug developers enhance drug delivery across the Blood-Brain Barrier (BBB) to enable effective treatments for neurodegenerative ...

BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) ...

today announced the launch of CANDID-CNS™, an attentive graph neural network for predicting the blood-brain barrier (BBB) permeability and distribution of small molecule drug candidates designed ...

AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a deal valued at $1.4bn ...

AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a ...

The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...

AbbVie acquires Aliada Therapeutics for $1.4 billion, enhancing Alzheimer's R&D with innovative blood-brain barrier ...